Ab­b­Vie dumps an ear­ly-stage drug in $225M Alzheimer's al­liance with Alec­tor

Back in No­vem­ber, as Bio­gen and the con­tro­ver­sy sur­round­ing Aduhelm soaked up the at­ten­tion around Alzheimer’s R&D, Alec­tor qui­et­ly pre­sent­ed Phase I da­ta for an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER